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In the current study, the thrombin generation marker F12 in
the clopidogrel group increased up to 24 h, whereas TAT, a
marker of thrombin activity, remained stable. An explanation
might be that clopidogrel could affect proteins that bind thrombin,
such as thrombomodulin or protease-activated receptors, thus
influencing the levels of circulating TAT.
In conclusion, rebound coagulation activity as reflected by
increasing thrombin generation occurs within hours after discon-
tinuation of low-molecular-weight heparin treatment. Clopidogrel
reduces this reactivation, and this might partially account for the
overall clinical benefits observed when adding clopidogrel to
aspirin treatment in ACS patients.
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Letters to the Editor
Pregnancy-Associated Plasma
Protein-A and Acute Coronary
Syndromes: Cause or Consequence?
Heeschen et al. (1) report an approximately two-fold risk of death
and myocardial infarction (MI) at 1 and 6 months linked with
pregnancy-associated plasma protein-A (PAPP-A) 12.6 mIU/l
among patients admitted for acute coronary syndromes (ACS),
even with normal troponin levels. The investigators hypothesize
plaque proteolysis by PAPP-A and harmful activation of insulin-
like growth factor-1 (IGF-1) through PAPP-A’s lysis of IGF-
binding proteins. We propose an alternative view.
Extracellular matrix degradation by PAPP-A, to our knowl-
edge, has never been documented. Moreover, IGF-1 exerts broad
cardiovascular protection, through insulin-sensitizing, nitric oxide–
mediated, antiapoptotic, regenerative, preconditioning, and anti-
inflammatory effects (2). How, then, can two apparently divergent
properties (predictor of risk for PAPP-A and vasculoprotective for
IGF-1) be reconciled?
Hypoxic/oxidative/inflammatory stress enhances PAPP-A’s
bioactivity (2–4). Circulating PAPP-A levels are increased in ACS
patients (1,4) and correlate (although not in all studies) with
indices of inflammation and myocardial damage (1,2,4). Experi-
mental damage raises local PAPP-A expression and IGF-1 bio-
activity (2,4) with immunomodulatory and anti-inflammatory
actions (4,5). During pregnancy, plasma PAPP-A is increased over
150-fold, with no parallel increase in ischemic risk; rather, reduced
PAPP-A predicts adverse outcomes (6). These data suggest that
PAPP-A is involved in physiological repair and replicative pro-
grams through its product, namely free IGF-1 (2–4).
Another circulating biomarker, B-type natriuretic peptide
(BNP), is cardioprotective and secreted in proportion to the extent
Table 1. Median Plasma Levels of Thrombin-Antithrombin Complex and of Prothrombin Fragment 12 in the Aspirin Plus
Clopidogrel and Aspirin-Alone Groups
Hours After Stopping
Enoxaparin
TAT (g/l) F12 (nmol/l)
12 0 3 6 12 24 48 12 0 3 6 12 24 48
Aspirin alone 4.6 4.1 6.8 6.7* 16.3† 17.0* 10.4 0.94 0.80 0.88* 0.97† 1.08† 1.14† 0.89
Aspirin plus clopidogrel 3.9 6.9 4.7 6.4 6.3 8.8 3.5 0.76 0.86 0.92* 0.98* 1.00* 1.34† 0.85
The p values are calculated in comparison to baseline (time 0) levels. Hour 0: 12 h after last enoxaparin dose. *p  0.05. †p  0.01.
F12  prothrombin fragment 12; TAT  thrombin-antithrombin complex.
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of ischemia. Elevated levels powerfully predict adverse events in
patients with coronary syndromes (7). Intravenous BNP (nesirit-
ide) is of proven benefit in managing cardiac patients.
Raised PAPP-A and BNP levels may be part of endogenous
compensatory pathways aimed at tissue salvage and repair. We
believe they strongly predict adverse outcomes because they are
sensitive signals of damage, without necessarily causing it.
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REPLY
We thank Dr. Conti and colleagues for their interesting contri-
bution regarding our recent study on the predictive value of
pregnancy-associated plasma protein-A (PAPP-A) in patients
with acute coronary syndromes (ACS) (1). As stated in the
discussion section of our report, the exact role of PAPP-A in the
pathophysiology in ACS still remains illusive. In this context, we
could only speculate about the putative role of the metalloprotein-
ase (MMP) PAPP-A in the setting of atherosclerotic plaque
destabilization, which may lead to clinical manifestation as an
ACS. We completely agree with Dr. Conti and colleagues that no
data are currently available directly demonstrating that PAPP-A
per se leads to degradation of extracellular matrix. However,
because matrix degradation has been shown for other MMPs, it is
quite reasonable to assume that PAPP-A may also act at least in
part through a similar mechanism.
Of note, release and subsequent activation of insulin-like
growth factor-1 (IGF-1), a potential protective factor in the
cardiovascular system, through PAPP-A activation may indeed
represent an alternative mechanism as suggested by Conti et al.
(2). Although this potential mechanism proposed by Dr. Conti
and co-workers is similarly reasonable and appealing, there is
also no definitive evidence that this is the most relevant
mechanism of action of PAPP-A in the setting of an ACS.
Unfortunately, we can neither support nor disprove the re-
searchers’ hypothesis as we did not have a chance to measure
IGF-1 levels in our study populations. Actually, it would not
seem to be appropriate to draw mechanistic conclusions from
this kind of clinical study. Circulating levels of biomarkers such
as PAPP-A only represent the integral of PAPP-A generation as
well as degradation in patients with ACS, but these studies alone
cannot provide any hint on the source and the mode of action of
PAPP-A in unstable atherosclerotic plaques, respectively. Thus,
one should be very cautious in drawing any definite mechanistic
conclusions from the levels of circulating biomarkers in any
disease. Apparently, further experimental studies are truly needed
to prove the exact role and mechanism of PAPP-A in atheroscle-
rosis and its complications.
In summary, we aimed in our study to place the biomarker
PAPP-A into the context of inflammation and matrix degradation
as this view is supported by the current literature (3–5). Indepen-
dent of the actual mechanism by which PAPP-A may contribute
to plaque destabilization and/or plaque healing, however, PAPP-A
remains an independent and powerful predictor for adverse events
in patients with ACS and, thus, deserves further investigation
regarding its clinical utility as a diagnostic biomarker.
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